EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Quality by Design and Process Analytical Technology for On-Demand Drug Manufacturing Through 3D Printing

Imola-Rebeka Turac iD, Tibor Casian, Sonia Iurian iD, Alina Porfire iD, Rareș Iovanov iD, Daniela Elena Popa iD, Ioan Tomuță iD

Pharmaceutics · 29.07.2026 · 18 (8) · 935

DOI: 10.3390/pharmaceutics18080935 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Pharmaceutics, online erschienen am 29.07.2026. Verfasst von Imola-Rebeka Turac und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmaceutical Technology and Biopharmacy, Faculty of Pharmacy, University of Medicine and Pharmacy "Iuliu Hatieganu", 41 Victor Babeș …. Die Arbeit nennt 184 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Iuliu Hațieganu University of Medicine and Pharmacy, University of Medicine and Pharmacy “Iuliu Hațieganu” Cluj-Napoca through the Doctoral Research Projects funding programme, Ministry of Investments and European Projects, through the Health Programme.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Additive manufacturing, also known as 3D printing (3DP), is intended to enable personalised medicine by producing drug products on demand at the Point of Care (PoC), with dose, drug-release profile, and geometry tailored to the individual patient. Despite its promise, widespread adoption is limited by the absence of ready-to-use quality control (QC) methods for printlets at the PoC. Process Analytical Technology (PAT) tools, particularly vibrational spectroscopic methods like Near-Infrared and Raman spectroscopy, can offer real-time monitoring to ensure the safety and consistency of printed dosage forms. Integrating these tools within a Quality-by-Design (QbD) framework can enhance process understanding, control variability, and minimise risk. Regulatory implementation and technological innovation remain essential for the broader clinical implementation of 3DP in pharmaceutical manufacturing. This review presents an overview of currently existing studies on PAT tools explored for non-destructive quality control across 3DP techniques, examines the correlation between Critical Process Parameters (CPPs), Critical Material Attributes (CMAs), and the Critical Quality Attributes (CQAs) of 3D-printed dosage forms within a QbD context, and outlines the current regulatory landscape alongside key limitations and future directions for the broader integration of 3DP into pharmaceutical development and manufacturing. Current evidence shows that PAT application remains uneven across printing technologies and is predominantly directed at final product quality control, rather than the real-time process monitoring required for a fully closed-loop QbD framework. Existing spectroscopic models are largely restricted to single formulations, printers, and APIs, and the absence of standardised validation reporting and transferability assessments represents a key barrier to routine implementation.

Schlagwörter

Stichwörter der Autor:innen

Process Analytical TechnologyQuality by Designpersonalised medicinepharmaceutical 3D printing

Autor:innen und Institutionen

  • Department of Pharmaceutical Technology and Biopharmacy, Faculty of Pharmacy, University of Medicine and Pharmacy "Iuliu Hatieganu", 41 Victor Babeș Street, 400012 Cluj-Napoca, Romania.
  • Department of Drug Control, Faculty of Pharmacy, "Carol Davila" University of Medicine and Pharmacy, 37 Dionisie Lupu Street, Sector 2, 020956 Bucharest, Romania.

ORCID-Profile: Imola-Rebeka Turac, Sonia Iurian, Alina Porfire, Rareș Iovanov, Daniela Elena Popa, Ioan Tomuță

Förderung

  • Iuliu Hațieganu University of Medicine and Pharmacy
  • University of Medicine and Pharmacy “Iuliu Hațieganu” Cluj-Napoca through the Doctoral Research Projects funding programme
  • Ministry of Investments and European Projects, through the Health Programme

Zitieren

APA

Turac, I. R., Casian, T., Iurian, S., Porfire, A., Iovanov, R., Popa, D. E., & Tomuță, I. (2026). Quality by Design and Process Analytical Technology for On-Demand Drug Manufacturing Through 3D Printing. Pharmaceutics, 18(8), 935. https://doi.org/10.3390/pharmaceutics18080935

Vancouver

Turac IR, Casian T, Iurian S, Porfire A, Iovanov R, Popa DE, et al. Quality by Design and Process Analytical Technology for On-Demand Drug Manufacturing Through 3D Printing. Pharmaceutics. 2026;18(8):935. doi:10.3390/pharmaceutics18080935

BibTeX
@article{Turac2026,
  author = {Turac, Imola-Rebeka and Casian, Tibor and Iurian, Sonia and Porfire, Alina and Iovanov, Rareș and Popa, Daniela Elena and Tomuță, Ioan},
  title = {Quality by Design and Process Analytical Technology for On-Demand Drug Manufacturing Through 3D Printing},
  journal = {Pharmaceutics},
  year = {2026},
  volume = {18},
  number = {8},
  pages = {935},
  doi = {10.3390/pharmaceutics18080935}
}
Kostenlos starten →